Selective serotonin reuptake inhibitor discontinuation syndrome: Understanding, recognition, and management for psychologists

Professional Psychology: Research and Practice

Volumn 30, Issue 5, 1999, Pages 464-469

  Rivas Vazquez, Rafael A ^a   Blais, Mark A ^a   Johnson, Sheri L ^a   Rey, Gustavo J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033241040     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.30.5.464     Document Type: Article

References (40)

1. Agelink, M. W., Zitzelsberger, A., & Lieser, E. (1997). Withdrawal syndrome after discontinuation of venlafaxine [Letter]. American Journal of Psychiatry, 154, 1473-1474.
2. Benazzi, F. (1998). Nefazodone withdrawal symptoms [Letter]. Canadian Journal of Psychiatry, 43, 194-195.
3. Black, D. W., Wesner, R., & Gabel, J. (1993). The abrupt discontinuation of fluvoxamine in patients with panic disorder. Journal of Clinical Psychiatry, 54, 146-149.
4. Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996). Serotonin reuptake inhibitor withdrawal. Journal of Clinical Psychopharmacology, 16, 356-362.
5. Dilsaver, S. C., & Greden, J. F. (1984). Antidepressant withdrawal phenomena. Biological Psychiatry, 19, 237-256.
6. Dilsaver, S. C., Greden, J. F., & Snider, R. M. (1987). Antidepressant withdrawal syndromes: Phenomenology and pathophysiology. International Clinical Psychopharmacology, 2, 1-19.
7. Dominguez, R. A., & Goodnick, P. J. (1995). Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy, 15, 778-780.
8. Farah, A., & Laurer, T. E. (1996). Possible venlafaxine withdrawal syndrome [Letter]. American Journal of Psychiatry, 153, 576.
9. Fava, M., Mulroy, R., Alpert, J., Nierenberg, A. A., & Rosenbaum, J. F. (1997). Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. American Journal of Psychiatry, 154, 1760-1762.
10. Fawcett, J. (1995). Compliance: Definitions and key issues. Journal of Clinical Psychiatry, 56(Suppl. 1), 4-8.
11. Frank, E., Kupfer, D. J., & Siegel, L. R. (1995). Alliance not compliance: A philosophy of outpatient care. Journal of Clinical Psychiatry, 56(Suppl. 1), 11-17.
12. Haddad, P. (1997). Newer antidepressants and the discontinuation syndrome. Journal of Clinical Psychiatry, 58(Suppl. 7), 17-21.
13. Halle, M. T., & Dilsaver, S. C. (1993). Tranylcypromine withdrawal phenomena. Journal of Psychiatry and Neuroscience, 18, 4-50.
14. Hollon, S. D., DeRubeis, R. J., Evans, M. D., Weimer, M. J., Garvey, M. J., Grove, W. M., & Tuason, V. B. (1992). Cognitive therapy and pharmacotherapy for depression: Singly and in combination. Archives of General Psychiatry, 49, 774-781.
15. Kaplan, E. M. (1997). Antidepressant noncompliance as a factor in the discontinuation syndrome. Journal of Clinical Psychiatry, 58(Suppl. 7), 31-35.
16. Katon, W., Von Korff, M., Lin, E., Walker, E., Simon, G. E., Busch, T., & Russo, N. (1995). Collaborative management to achieve treatment guidelines: Impact on depression in primary care. Journal of the American Medical Association, 273, 1026-1031.
17. Lazowick, A. (1995). Potential withdrawal syndrome associated with SSRI discontinuation. Annals of Pharmacotherapy, 29, 1284-1285.
18. Lejoyeux, M., & Ades, J. (1997). Antidepressant discontinuation: A review of the literature. Journal of Clinical Psychiatry, 58(Suppl. 7), 11-15.
19. Mallya, G., White, K., & Gunderson, C. (1993). Is there a serotonergic withdrawal syndrome? Biological Psychiatry, 33, 851-852.
20. Mann, A. M., & MacPherson, A. S. (1959). Clinical experience with imipramine (G22355) in the treatment of depression. Canadian Psychiatric Association Journal, 4, 38-47.
21. Mucci, M. (1997). Reboxetine: A review of antidepressant tolerability. Journal of Psychopharmacology, 11(Suppl. 4), 33-37.
22. Muldoon, C. (1996). The safety and tolerability of citalopram. International Clinical Psychopharmacology, 11(Suppl. 1), 35-40.
23. Otto, M. W., Pollack, M. H., Sachs, G. S., Reiter, S. R., Meltzer-Brody, S., & Rosenbaum, J. F. (1993). Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder. American Journal of Psychiatry, 150, 1485-1490.
24. Pacheco, L., Malo, P., Aragues, E., & Etxebeste, M. (1996). More cases of paroxetine withdrawal syndrome [Letter]. British Journal of Psychiatry, 169, 384.
25. Parker, G., & Blennerhassett, J. (1998). Withdrawal reactions associated with venlafaxine. Australian & New Zealand Journal of Psychiatry, 32, 291-294.
26. Paykel, E. S. (1995). Psychotherapy, medication combinations, and compliance. Journal of Clinical Psychiatry, 56(Suppl. 1), 24-30.
27. Physicians' desk reference (53rd ed.). (1999). Montvale, NJ: Medical Economics Company.
28. Pies, R. (1998). Treatment challenges in depressive disorders. Psychiatric Times, 15(Suppl.), 1-4.
29. Preskorn, S. H. (1993). Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. Journal of Clinical Psychiatry, 54(Suppl. 9), 14-34.
30. Priest, R. G., Vize, C., Roberts, M., & Tylee, A. (1996). Lay people's attitudes to treatment of depression: Results from opinion poll for Defeat Depression Campaign just before launch. British Medical Journal, 313, 858-859.
31. Rivas-Vazquez, R., & Blais, M. (1997). Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28, 526-536.
32. Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry, 44, 77-87.
33. Rosenbaum, J. F., & Zajecka, J. (1997). Clinical management of antidepressant discontinuation. Journal of Clinical Psychiatry, 58(Suppl. 7), 37-40.
34. Schatzberg, A. F. (1998). Discontinuation symptoms and SSRIs [Letter]. Journal of Clinical Psychiatry, 59, 535-537.
35. Schatzberg, A. F., Haddad, P., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997a). Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Journal of Clinical Psychiatry, 58(Suppl. 7), 23-27.
36. Schatzberg, A. F., Haddad, P., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997b). Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Journal of Clinical Psychiatry, 58(Suppl. 7), 5-10.
37. Stahl, S. M. (1998). Basic psychopharmacology of antidepressants: Part 1. Antidepressants have seven distinct mechanisms of action. Journal of Clinical Psychiatry, 59(Suppl. 4), 5-14.
38. Thompson, C. (1998). Discontinuation of antidepressant therapy: Emerging complications and their relevance. Journal of Clinical Psychiatry, 59, 541-548.
39. Young, A. H., & Currie, A. (1997). Physician's knowledge of antidepressant withdrawal effects: A survey. Journal of Clinical Psychiatry, 58(Suppl. 7), 28-30.
40. Zajecka, J., Tracy, K. A., & Mitchell, S. (1997). Discontinuation symptoms after treatment with serotonin reuptake inhibitor: A literature review. Journal of Clinical Psychiatry, 58, 291-297.